---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-206655"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2024-08-26T23:59:59+00:00"
generated_at: "2026-05-31T07:41:08.879067+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Eliem Therapeutics appoints Brett Kaplan as COO with equity grants

## Summary
- Brett Kaplan, M.D., appointed Chief Operating Officer effective August 26, 2024.
- Base salary of $500,000/year; eligible for annual bonus up to 45% of base salary.
- Granted option to purchase 465,000 shares and 77,500 RSUs under 2021 Equity Incentive Plan.
- Option vests 25% at one year then monthly over 3 years; RSUs vest 25% annually over 4 years.
- Severance: 9 months salary (non-CIC) or 12 months plus target bonus (CIC), plus COBRA and equity acceleration.

## SEC filing metadata
- accession: 0001193125-24-206655
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2024-08-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312524206655/0001193125-24-206655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312524206655/d866047d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-206655
- JSON: https://secwatch.observer/filing/0001193125-24-206655.json
- Plain text: https://secwatch.observer/filing/0001193125-24-206655.txt

## Key facts
- Executive change
  Brett Kaplan, M.D. was appointed as Chief Operating Officer at Climb Bio, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On August 26, 2024, Eliem Therapeutics, Inc. (the “Company”) announced that its board of directors (the “Board”) had appointed Brett Kaplan, M.D., as Chief Operating Officer of the Company, effective August 26, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312524206655/0001193125-24-206655-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.